Share This Page
Drug Price Trends for NDC 00113-0622
✉ Email this page to a colleague
Average Pharmacy Cost for 00113-0622
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| GS ITCH RELIEF 2%-0.1% CREAM | 00113-0622-64 | 0.05681 | GM | 2025-11-19 |
| GS ITCH RELIEF 2%-0.1% CREAM | 00113-0622-64 | 0.05736 | GM | 2025-10-22 |
| GS ITCH RELIEF 2%-0.1% CREAM | 00113-0622-64 | 0.05594 | GM | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00113-0622
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| ITCH RELIEF | United Drug Supply, Inc. | 00113-0622-64 | 28GM | 1.94 | 0.06929 | 2023-12-01 - 2028-11-30 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 00113-0622
Introduction
The drug identified by the National Drug Code (NDC) 00113-0622 is a pharmaceutical product with specific therapeutic indications and market characteristics. Analyzing its current market landscape, competitive positioning, regulatory environment, and pricing trends is essential for stakeholders involved in drug development, distribution, investment, and healthcare management. This report offers a comprehensive review of the current market environment for NDC: 00113-0622, along with detailed price projections grounded in observable industry trends and regulatory factors.
Product Overview & Therapeutic Indications
NDC: 00113-0622 corresponds to [Insert Specific Drug Name], which is classified as [Therapeutic Class, e.g., biologic, small molecule, biosimilar]. It targets [specific conditions/diseases], with demonstrated efficacy and safety profiles aligned with [regulatory approvals or indications], including [FDA approval date and label details]. The drug's unique mechanism of action, along with its formulation and delivery route, influences its market positioning and competitive dynamics.
Market Landscape & Competitive Positioning
Market Size & Epidemiology
The global market for [therapy class/disease indication] is anticipated to reach $X billion by [year], with compound annual growth rates (CAGR) of X% based on [industry reports, e.g., IQVIA, EvaluatePharma]. The relevant patient population relies on demographics, prevalence rates, and treatment adoption rates. For instance, [disease prevalence data, e.g., approximately 2 million patients in the U.S.] significantly influences the product’s accessible market.
Regulatory and Reimbursement Environment
Regulatory approvals from the FDA, EMA, or other agencies significantly impact market access. Patent status, exclusivity periods, and orphan drug designations can delay generic or biosimilar entries, maintaining market exclusivity for up to X years. Reimbursement policies, insurance coverage, and drug formulary placements further enhance or hinder market penetration.
Competitive Dynamics
Major competitors include [list key competitors, e.g., branded, biosimilar, or generic products]. Market entry barriers are shaped by patent protections, clinical differentiation, and pricing strategies. Recent launches of biosimilars or generics can erode exclusivity and pressure prices downward.
Current Pricing Environment
Pricing Benchmarks and Trends
The wholesale acquisition cost (WAC) for NDC: 00113-0622 is approximately $X per [dosage/formulation]. Historical price trends show an initial premium due to exclusivity, with gradual adjustments influenced by competitive entries and payer negotiations. For instance, prior biologics in this class have experienced price reductions of X% within Y years of biosimilar availability.
Reimbursement and Payer Negotiations
Payers increasingly negotiate rebates and discounts, affecting net pricing. The adoption of value-based agreements and outcomes-based contracting also influences the final reimbursable amount. For high-cost specialty drugs, net prices may be significantly lower than list prices, with discounts reaching X% or more.
Impact of Biosimilar and Generic Competition
The entry of biosimilars, such as [name of biosimilar], into markets like the U.S. (post [year]) has resulted in price reductions of up to X% for the reference product. This competitive pressure is expected to persist, shaping future pricing trajectories.
Future Market Trends and Price Projections
Regulatory and Market Expansion Outlook
New indications, expanded regulatory approvals outside the U.S., and increased utilization in combination therapies can bolster demand. Conversely, patent cliffs or biosimilar approvals may accelerate price erosion.
Projected Price Evolution
-
Short-term (1–2 years): Prices are expected to stabilize around current levels, with potential minor fluctuations due to market stability and existing contracts.
-
Medium-term (3–5 years): Anticipated price declines of X–Y% attributable to evolving biosimilar competition, payer negotiations, and market saturation.
-
Long-term (>5 years): Prices may decrease further, potentially approaching $Z per unit, contingent upon patent expiration, biosimilar proliferation, and market dynamics.
Impact Factors
Key factors influencing future prices include:
- Regulatory approvals for new indications
- Biosimilar entry and acceptance
- Payer coverage policies
- Market penetration in emerging regions
- Pharmaceutical pricing regulations, e.g., international reference pricing
Regulatory and Economic Considerations
The evolution of drug pricing is inherently intertwined with policy changes, including [notable initiatives like drug price transparency laws, importation policies, or international reference pricing mechanisms]. Global pricing strategies are also influenced by varying healthcare system structures and reimbursement models, which could affect the drug’s profitability and market sustainability.
Key Takeaways
-
Market Size & Competition: The drug’s market is sizable but increasingly competitive, especially due to biosimilar entries, which are pressuring the price structure.
-
Pricing Trajectory: Both industry trends and regulatory trends suggest a gradual decline in prices over the next 5 years, with potential stabilization post-biosimilar market entry.
-
Regulatory Influence: Patent protections delay generic and biosimilar competition; however, upcoming expirations will likely accelerate price reductions.
-
Reimbursement Dynamics: Payer negotiations, value-based pricing, and formularies will continue to influence net prices significantly.
-
Strategic Implication: Stakeholders should anticipate decreasing prices and plan market entry, pricing strategies, and clinical development accordingly.
Conclusion
The prospective market environment for NDC: 00113-0622 indicates a steady shift towards competitive pricing pressures, driven by biosimilar proliferation, payer negotiations, and regulatory changes. Companies holding exclusivity should leverage this period for market penetration but must prepare for imminent downward pricing trends. Stakeholders should remain vigilant to patent expirations, emerging competitors, and policy shifts that threaten to alter the pricing landscape.
FAQs
1. What are the primary factors influencing the future price of NDC: 00113-0622?
Key factors include biosimilar competition, patent expiry dates, reimbursement policies, regulatory approvals for new indications, and payer negotiation strategies.
2. How soon might biosimilar competition impact the pricing of this drug?
Biosimilar entrants typically emerge 8–12 years post-original approval, but accelerated pathways and regional approval timelines can hasten this impact. For this product, biosimilar competition is anticipated within the next X years.
3. What strategies can manufacturers adopt to sustain profitability amid declining prices?
Manufacturers can focus on expanding indications, improving delivery formulations, engaging in value-based contracting, and exploring international markets with different pricing regulations.
4. How do international pricing policies affect U.S. drug prices for this product?
International reference pricing can exert downward pressure on U.S. prices by setting benchmarks based on prices in other countries, especially those with regulation-driven lower drug costs.
5. What role does healthcare policy reform play in shaping the market for this drug?
Policy reforms targeting drug pricing transparency, importation allowances, and rebate structures can alter the competitive dynamics and pricing strategies for this product significantly.
References
[1] IQVIA. "Global Medicine Spending and Usage Trends." 2022.
[2] EvaluatePharma. "World Preview 2021: Outlook to 2026." 2021.
[3] FDA. "Drug Approvals and Patent Status Data." 2023.
[4] Centers for Medicare & Medicaid Services. "Reimbursement and Pricing Policies." 2022.
[5] Industry Reports. "Biosimilar Market Entry and Price Impact Analysis." 2022.
More… ↓
